LAS VEGAS, NV / ACCESSWIRE / September 18, 2014 / Cytta Corp., CYCA, is extremely pleased to announce, the next step in realizing the Company's vision, the acquisition of "ClinicalwoRx(TM) Inc." ClinicalwoRx(TM) (http://clinicalworx.com/) brings a national network of specialized sales professionals who present unique medical products and services to healthcare providers in all major metropolitan areas of the US.
The ClinicalwoRx(TM) team of medical sales professionals will form the backbone of the Cytta/EraStar Medical team by creating the sales funnel for our new and innovative products. By offering physicians new and exclusive practice opportunities, such as needle free Allergy management (AllergywoRx(TM)), new comprehensive pain management (PainwoRx(TM)) and new genetic and toxicology testing (TestwoRx(TM)), we can greatly enhance the patient care, outcomes and profitability of a medical practice. As a result, caring for patients becomes more efficient, more convenient and more profitable.
Gary Campbell, Cytta CEO stated, "The acquisition of ClinicalwoRx(TM) fits perfectly with our recently announced definitive merger with EraStar, Inc. and their subsidiary, EraStar Medical, Inc. and Cytta's breakthrough " Doctor Direct " remote telemedicine program by providing a national sales network, marketing support and implementation team. AllergywoRx(TM) will be the first official program to launch nationwide within the next few weeks. This launch will provide immediate brand recognition of future "woRx" programs and is projected to generate significant revenues in before year end 2014. The rapid launch of the program is essential for maximizing sales during the lucrative fall allergy season. We will now be able to offer Doctors an effective way to treat patients suffering from environmental allergies while establishing a lucrative recurring revenue base for their medical practice. We are thrilled to bring this breakthrough technology to the marketplace today."
About EraStar, Inc.
EraStar, Inc. is a dynamic Las Vegas based marketing business that offers the following services: Comprehensive Marketing Strategies for Public and Private Institutions, Public Relations and Media Activities, Product Marketing, Support Services, Business Development Consulting, and Lead Generation. EraStar currently provides services to variety of clients in a number of industries nationwide.
About EraStar Medical, Inc.
EraStar Medical Inc. (EMI) a subsidiary of EraStar Inc. creates a structure within its parent company that allows management to apply their advisory services and med-tech acquisitions specifically in the booming med-tech sector. EMI's connectivity and analytics platform provides predictive and intelligent clinical knowledge across the spectrum of individualized health and wellness care. EraStar Medical seeks to provide cost efficient technical strategies that will create superior healthcare outcomes for physicians and patients globally.
About Cytta Corp.
Cytta Corp. is an open source remote monitoring ubiquitous connectivity platform known for its highly scalable and secure Healthcare telehealth solutions. In addition to the Doctor Direct program and the Hospital re-admission program, we are now offering the Cytta Connect technology to the Oil & Gas industry. Our remote data capture highway, which connects monitoring devices seamlessly to a cloud-based data repository, is now fully operational and offered in these selected segments. Our remote data capture system works over our Special Purpose Network utilizing 4G LTE AT&T domestic and international SIMS, a proprietary smartphone based, Mobile, Satellite, and WiFi open source platform, and cloud-based data repository. The Cytta Connect technology automatically connects all remote monitoring devices to Cytta's cloud-based data repository creating real time communication for the Healthcare/Telehealth and Oil & Gas industries.
Safe Harbor Statement/ Forward-Looking Statements
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward looking statements, whether as a result of future events, new information, or otherwise.
CONTACT:
Cytta Corp.
Mr. Gary Campbell, CEO
Office (702) 307-1680
Email: Gary@Cytta.com
Website: www.Cytta.com
EraStar, Inc.
Ms. Vanessa Luna, COO
Las Vegas, NV
702 480 9800 office
Website: www.erastar.com
SOURCE: Cytta Corp.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
